Pharmaceutical

How to transform EHR data into useful clinical insights...

AI and machine learning can transform fragmented and unstructured healthcare dat...

Pharma faces 30-day deadline under Trump’s pricing order

US President Donald Trump has signed an executive order telling drugmakers to cu...

EC grants orphan drug status to Biodexa’s oral FAP trea...

The European Commission (EC) has granted orphan drug designation to Biodexa Phar...

Republicans’ proposed Medicaid cuts met with dismay

The Trump administration has introduced legislation outlining plans for deep cut...

Abeona secures cash runway with $155m priority review v...

Abeona’s deal value is in line with recent voucher sale transactions amid uncert...

GSK and iTeos drop anti-TIGIT drug following trial failure

This follows what appeared to be a generally positive data readout for belrestot...

Lilly-Purdue partnership to invest $250m in pharma inno...

Eli Lilly and Purdue University, US, have announced the widening of their existi...

VC firm Vivo Capital outlays $740m for biotech investment

Vivo Capital has previously backed biotechs acquired by big pharma in billion-do...

BioVaxys and Sona partner to develop cancer therapeutics

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer...

5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, ...

Globaldata's analysis focuses on three key indicators, which include HTA outcome...

HLS Therapeutics and Esperion partner to commercialise ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for commerci...

Bavarian Nordic shares rise 7% following strong Q1 for ...

Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscap...

NewBiologix licenses cell line technology to Recipharm ...

NewBiologix has given a non-exclusive technology licence to Recipharm Advanced B...

FDA chief Martin Makary sets June deadline for genAI ro...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to im...

Haya secures $65m in Series A funds to advance heart fa...

Haya Therapeutics has secured $65m in Series A funding to expedite the clinical ...